Moderna says COVID-19 vaccine safe and effective for teens, adolescents; will seek expanded FDA approval
Moderna today said its two-dose COVID-19 vaccine is safe and effective for individuals between 12 and 17 years old, citing data from its ongoing phase 2/3 clinical trial of 3,700 participants. Moderna reported a vaccine efficacy of 93% within 14 days of trial participants’ first dose, with zero reported cases of symptomatic COVID-19 two weeks after their final dose. Moderna said it will submit its data to the Food and Drug Administration in early June as part of a requested expansion of its emergency use authorization to include teens and adolescents.
Related News Articles
Headline
AHA's latest social media toolkit for encouraging vaccination against the flu and COVID-19 provides fall-themed social media posts and graphics. Download the…
Headline
The Centers for Disease Control and Prevention last week endorsed a recommendation for people aged 65 and older and for immunocompromised individuals to…
Headline
The Centers for Disease Control and Prevention is reminding clinicians and other health care workers to take necessary steps to keep themselves and their…
Chairperson's File
Autumn is here, and that means cooler weather and also the start of flu season.We know the best way to prevent influenza is to get a flu vaccine. The Centers…
Headline
The National Foundation for Infectious Diseases Sept. 25 released a survey showing that less than one in five U.S. adults are concerned about themselves or a…
Headline
The Food and Drug Administration Aug. 22 granted emergency use authorization for two new combined COVID-19 and influenza tests. The Nano-Check Influenza-COVID-…